RhumbLine Advisers
APRE icon

RhumbLine Advisers’s Aprea Therapeutics APRE Stock Holding History

RhumbLine Advisers’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-398
Closed -$309K – 2977
2020
Q2 		$309K Buy
398
+80
+25% +$52.5K ﹤0.01% 2562
2020
Q1 		$221K Buy
+318
New +$233K ﹤0.01% 2539

Other funds holding APRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RhumbLine Advisers's APRE Position: Q3 2020 in Review

RhumbLine Advisers sold out of Aprea Therapeutics (APRE) in Q3 2020, closing a stake of 398 shares — an estimated $309K sold.

RhumbLine Advisers first reported a position in APRE in Q1 2020 and held it in 2 quarters. The position peaked at $309K in Q2 2020. 64 funds tracked by Wall St. Rank hold APRE as of Q3 2020.

  • RhumbLine Advisers reported no remaining Aprea Therapeutics position as of Q3 2020 after selling out during the quarter.
  • RhumbLine Advisers sold 398 Aprea Therapeutics shares in Q3 2020, an estimated $309K.
  • RhumbLine Advisers first reported a position in Aprea Therapeutics in Q1 2020 and held it in 2 quarters.
  • RhumbLine Advisers's Aprea Therapeutics position peaked at $309K in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2020.

Based on RhumbLine Advisers's 13F filing for Q3 2020, filed 12 Nov 2020.